Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: A systematic review

被引：30
作者：
Marinos C. Makris
Konstantinos A. Polyzos
Michael N. Mavros
Stavros Athanasiou
Petros I. Rafailidis
Matthew E. Falagas
机构：
[1] Alfa Institute of Biomedical Sciences (AIBS), Athens, 151 23 Marousi
[2] Department of Obstetrics and Gynecology, Athens University School of Medicine, Athens
[3] Department of Medicine, Henry Dunant Hospital, Athens
[4] Department of Medicine, Tufts University School of Medicine, Boston, MA
来源：
Drug Safety | 2012年 / 35卷 / 1期
关键词：
Congenital-abnormalities; Fetal-death; Fetus; Hepatitis-B-vaccine; Immunisation; Meningococcal-vaccine-polysaccharide; Neonatal-disorders; Neonates; Pneumococcal-vaccines; Pregnancy;
D O I：
10.2165/11595670-000000000-00000
中图分类号：
学科分类号：
摘要：
Immunization during pregnancy has the potential to protect the mother and the newborn from preventable diseases. Current recommendations suggest that inactivated vaccines might be considered during pregnancy when the benefits outweigh the risks.In this review, we aimed to evaluate the safety of hepatitis B (HB) vaccine, pneumococcal polysaccharide vaccine (PPSV) and meningococcal polysaccharide vaccine (MPSV) administration during pregnancy by systematically reviewing the available evidence in PubMed and Scopus databases, as well as postmarketing surveillance data (including the Vaccine Adverse Event Reporting System VAERS database). A total of 18 studies were eligible for inclusion in the review. Six studies provided data on HB vaccine, six on PPSV and three on MPSV; three additional studies compared PPSV with MPSV. Additionally, 91 reports on vaccinations of pregnant women were identified from postmarketing surveillance data (88 on HB vaccine, 2 on PPSV, 1 on MPSV). The most common complaints were local reactions, including tenderness and swelling. Overall, immunization during pregnancy did not seem to be associated with a teratogenic effect on the fetus, preterm labour or spontaneous abortion. However, the lack of randomized, placebo-controlled trials, or even large cohort studies, in addition to the inherent limitations of the reviewed observational studies with small statistical power, precluded safe conclusions. Large, prospective, population-based cohort studies are needed to elucidate this issue.
引用
收藏
页码：1 / 14
页数：13
相关论文
共 56 条
  • [1] Gruslin A., Steben M., Halperin S., Et al., Immunization in pregnancy: No. 220, December 2008, Int J Gynaecol Obstet, 105, pp. 187-191, (2009)
  • [2] Munoz F.M., Englund J.A., Vaccines in pregnancy, Infectious Disease Clinics of North America, 15, 1, pp. 253-271, (2001)
  • [3] Falagas M.E., Vouloumanou E.K., Baskouta E., Et al., Treatment options for 2009 H1N1 influenza: Evaluation of the published evidence, Int J Antimicrob Agents, 35, pp. 421-430, (2010)
  • [4] Siston A.M., Rasmussen S.A., Honein M.A., Et al., Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States, JAMA, 303, pp. 1517-1525, (2010)
  • [5] Louie J.K., Acosta M., Jamieson D.J., Et al., Severe 2009 H1N1 influenza in pregnant and postpartum women in California, N Engl J Med, 362, pp. 27-35, (2010)
  • [6] Fischer G.W., Ottolini M.G., Mond J.J., Prospects for vaccines during pregnancy and in the newborn period, Clinics in Perinatology, 24, 1, pp. 231-249, (1997)
  • [7] Gruber M.F., Maternal immunization: US FDA regulatory considerations, Vaccine, 21, 24, pp. 3487-3491, (2003)
  • [8] Guidelines for Vaccinating Pregnant Women: From Recommendations of the Advisory Committee on Immunization Practices (ACIP), (2007)
  • [9] Mak T.K., Mangtani P., Leese J., Watson J.M., Pfeifer D., Influenza vaccination in pregnancy: Current evidence and selected national policies, The Lancet Infectious Diseases, 8, 1, pp. 44-52, (2008)
  • [10] Skowronski D.M., De Serres G., Is routine influenza immunization warranted in early pregnancy?, Vaccine, 27, pp. 4754-4770, (2009)
123456